Dowling & Yahnke’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2022
Q3 | $18M | Sell |
55,632
-37
| -0.1% | -$11.7K | 0.84% | 28 |
|
|
2022
Q2 | $18.1M | Buy |
55,669
+29
| +0.1% | +$8.71K | 0.85% | 28 |
|
|
2022
Q1 | $15.9M | Sell |
55,640
-382
| -0.7% | -$98.3K | 0.69% | 32 |
|
|
2021
Q4 | $15.5M | Sell |
56,022
-639
| -1% | -$162K | 0.74% | 30 |
|
|
2021
Q3 | $13.1M | Sell |
56,661
-300
| -0.5% | -$74K | 0.72% | 30 |
|
|
2021
Q2 | $13.1M | Buy |
56,961
+204
| +0.4% | +$41K | 0.75% | 30 |
|
|
2021
Q1 | $10.6M | Sell |
56,757
-347
| -0.6% | -$67.9K | 0.72% | 35 |
|
|
2020
Q4 | $9.64M | Buy |
57,104
+2,101
| +4% | +$314K | 0.69% | 36 |
|
|
2020
Q3 | $8.14M | Sell |
55,003
-1,553
| -3% | -$240K | 0.65% | 42 |
|
|
2020
Q2 | $9.29M | Sell |
56,556
-1,668
| -3% | -$256K | 0.78% | 31 |
|
|
2020
Q1 | $8.08M | Sell |
58,224
-2,324
| -4% | -$319K | 0.78% | 30 |
|
|
2019
Q4 | $7.96M | Sell |
60,548
-159
| -0.3% | -$18.4K | 0.61% | 48 |
|
|
2019
Q3 | $6.79M | Buy |
60,707
+1,090
| +2% | +$121K | 0.56% | 58 |
|
|
2019
Q2 | $6.61M | Buy |
59,617
+390
| +0.7% | +$45.9K | 0.55% | 58 |
|
|
2019
Q1 | $7.68M | Sell |
59,227
-282
| -0.5% | -$34.3K | 0.74% | 40 |
|
|
2018
Q4 | $7.06M | Buy |
59,509
+600
| +1% | +$67K | 0.73% | 44 |
|
|
2018
Q3 | $6.32M | Sell |
58,909
-680
| -1% | -$68K | 0.55% | 62 |
|
|
2018
Q2 | $5.08M | Buy |
59,589
+179
| +0.3% | +$14.7K | 0.47% | 70 |
|
|
2018
Q1 | $4.6M | Sell |
59,410
-2,137
| -3% | -$172K | 0.43% | 79 |
|
|
2017
Q4 | $5.2M | Sell |
61,547
-287
| -0.5% | -$24.4K | 0.47% | 72 |
|
|
2017
Q3 | $5.29M | Buy |
61,834
+259
| +0.4% | +$21.2K | 0.54% | 68 |
|
|
2017
Q2 | $5.07M | Buy |
61,575
+544
| +0.9% | +$44.4K | 0.53% | 69 |
|
|
2017
Q1 | $5.13M | Buy |
61,031
+569
| +0.9% | +$45.6K | 0.55% | 64 |
|
|
2016
Q4 | $4.45M | Sell |
60,462
-1,535
| -2% | -$114K | 0.5% | 71 |
|
|
2016
Q3 | $4.98M | Sell |
61,997
-623
| -1% | -$49.9K | 0.58% | 59 |
|
|
2016
Q2 | $4.93M | Buy |
62,620
+1,662
| +3% | +$125K | 0.59% | 55 |
|
|
2016
Q1 | $4.39M | Buy |
60,958
+2,504
| +4% | +$189K | 0.54% | 60 |
|
|
2015
Q4 | $4.92M | Sell |
58,454
-582
| -1% | -$48.3K | 0.62% | 50 |
|
|
2015
Q3 | $4.94M | Buy |
59,036
+203
| +0.3% | +$17.1K | 0.67% | 45 |
|
|
2015
Q2 | $4.91M | Sell |
58,833
-372
| -0.6% | -$28.3K | 0.62% | 56 |
|
|
2015
Q1 | $4.3M | Sell |
59,205
-1,220
| -2% | -$86.9K | 0.54% | 64 |
|
|
2014
Q4 | $4.17M | Sell |
60,425
-74
| -0.1% | -$5K | 0.52% | 70 |
|
|
2014
Q3 | $3.92M | Buy |
60,499
+6
| +0% | +$380 | 0.52% | 67 |
|
|
2014
Q2 | $3.76M | Sell |
60,493
-768
| -1% | -$45.8K | 0.49% | 71 |
|
|
2014
Q1 | $3.61M | Buy |
61,261
+502
| +0.8% | +$28K | 0.48% | 71 |
|
|
2013
Q4 | $3.1M | Buy |
60,759
+916
| +2% | +$45.9K | 0.44% | 78 |
|
|
2013
Q3 | $3.01M | Sell |
59,843
-85
| -0.1% | -$4.45K | 0.47% | 77 |
|
|
2013
Q2 | $2.94M | Buy |
+59,928
| New | +$3.26M | 0.49% | 73 |
|
Other funds holding LLY
Dowling & Yahnke's LLY Position: Q3 2022 in Review
Dowling & Yahnke reduced its Eli Lilly (LLY) stake by 0.07% in Q3 2022, selling an estimated $11.7K and leaving 55,632 shares worth $18M. The position accounts for 0.84% of the portfolio, ranked #28.
Dowling & Yahnke first reported a position in LLY in Q2 2013 and has held it in 38 quarters since. The position peaked at $18.1M in Q2 2022. 2,485 funds tracked by Wall St. Rank hold LLY as of Q3 2022.
- Dowling & Yahnke held 55,632 shares of Eli Lilly worth $18M as of Q3 2022.
- Dowling & Yahnke sold 37 Eli Lilly shares in Q3 2022, an estimated $11.7K.
- Eli Lilly made up 0.84% of Dowling & Yahnke's portfolio in Q3 2022, its #28 holding.
- Dowling & Yahnke first reported a position in Eli Lilly in Q2 2013 and has held it in 38 quarters since.
- Dowling & Yahnke's Eli Lilly position peaked at $18.1M in Q2 2022.
- 2,485 funds tracked by Wall St. Rank held Eli Lilly as of Q3 2022.
Based on Dowling & Yahnke's 13F filing for Q3 2022, filed 3 Nov 2022.